A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

被引：27

作者：

Diekema, Daniel J. ^{[1
,2
]}

Messer, Shawn A. ^{[2
]}

Hollis, Richard J. ^{[2
]}

Boyken, Linda ^{[2
]}

Tendolkar, Shailesh ^{[2
]}

Kroeger, Jennifer ^{[2
]}

Jones, Ronald N. ^{[4
]}

Pfaller, Michael A. ^{[2
,3
]}

机构：

[1] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA

[2] Univ Iowa, Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA

[3] Univ Iowa, Carver Coll Med, Dept Epidemiol, Iowa City, IA 52242 USA

[4] Jones Microbiol Inst, N Liberty, IA 52317 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2009年 / 63卷 / 02期

关键词：

Voriconazole; Surveillance; Candida; IN-VITRO ACTIVITIES; ANTIFUNGAL SUSCEPTIBILITY; RECEIVING VORICONAZOLE; FUNGAL-INFECTIONS; UNITED-STATES; SURVEILLANCE; FLUCONAZOLE; GLABRATA; FUNGEMIA; SPP;

D O I：

10.1016/j.diagmicrobio.2008.11.001

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Voriconazole susceptibility testing was performed on 7191 Candida spp. from 78 centers worldwide between 2004 and 2007. Voriconazole was very active in vitro (MIC50/MIC90, 0.008/0.25 mu g/mL; 98% susceptible). In comparison to 5866 Candida spp. isolates collected during global Surveillance from 1997 to 2001, there were no changes in voriconazole mean MIC or MIC distribution. (c) 2009 Elsevier Inc. All rights reserved.

引用

页码：233 / 236

页数：4

共 19 条

[1] Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazol [J].

Alexander, BD ;

Schell, WA ;

Miller, JL ;

Long, GD ;

Perfect, JR .

TRANSPLANTATION, 2005, 80 (06) :868-871

[2] Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility [J].

Arendrup, M. C. ;

Fuursted, K. ;

Gahrn-Hansen, B. ;

Schonheyder, H. C. ;

Knudsen, J. D. ;

Jensen, I. M. ;

Bruun, B. ;

Christensen, J. J. ;

Johansen, H. K. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (05) :487-494

[3]

GONZALEZ GM, 2008, J CLIN MICROBIOL

[4] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[5] Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole [J].

Imhof, A ;

Balajee, SA ;

Fredricks, DN ;

Englund, JA ;

Marr, KA .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) :743-746

[6] Voriconazole: A new triazole antifungal agent [J].

Johnson, LB ;

Kauffman, CA .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :630-637

[7] Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial [J].

Kullberg, BJ ;

Sobel, JD ;

Ruhnke, M ;

Pappas, PG ;

Viscoli, C ;

Rex, JH ;

Cleary, JD ;

Rubinstein, E ;

Church, LWP ;

Brown, JM ;

Schlamm, HT ;

Oborska, IT ;

Hilton, F ;

Hodges, MR .

LANCET, 2005, 366 (9495) :1435-1442

[8]

National Committee for Clinical Laboratory Standards, 2002, M27A2 NAT COMM CLIN

[9] Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States [J].

Ostrosky-Zeichner, L ;

Rex, JH ;

Pappas, PG ;

Hamill, RJ ;

Larsen, RA ;

Horowitz, HW ;

Powderly, WG ;

Hyslop, N ;

Kauffman, CA ;

Cleary, J ;

Mangino, JE ;

Lee, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3149-3154

[10] Voriconazole treatment for less-common, emerging, or refractory fungal infections [J].

Perfect, JR ;

Marr, KA ;

Walsh, TJ ;

Greenberg, RN ;

DuPont, B ;

de la Torre-Cisneros, J ;

Just-Nübling, G ;

Schlamm, HT ;

Lutsar, I ;

Espinel-Ingroff, A ;

Johnson, E .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1122-1131

← 1 2 →